Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 13/20 | 0.38 |
| ▸ | ATRIP | Q8WXE1 | 12/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 11/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 11/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 11/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 4/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | PDE1A | P54750 | 1/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28584100 | 0.88 | MTOR (0.42) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL23408531 | 0.88 | MTOR (0.42) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL29738240 | 0.88 | MTOR (0.42) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL23629214 | 0.81 | ATR (0.43) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL24024124 | 0.80 | ATR (0.37) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL28577382 | 0.79 | ATR (0.43) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL28577379 | 0.79 | ATR (0.43) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL24024162 | 0.78 | PDE1A (0.31) | PDE1APDE1BPDE1C | |
| SCHEMBL28584788 | 0.75 | ATR (0.47) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL28584789 | 0.75 | ATR (0.47) | ATRATRIPCHEK1PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355123-A1 | 5-Morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives | MERCK PATENT GMBH (DE) | 2021-11-18 | — | — | US | disclosed |
| EP-3846904-A1 | 5-MORPHOLIN-4-YL-PYRAZOLO[4,3-B]PYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2021-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355123-A1 | 5-Morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives | ATR, CDK1, CDKN1A | ATR 1/4885ATRIP 7/4885CHEK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.